Next 10 |
Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...
2023-04-03 00:36:41 ET Neovasc press release ( NASDAQ: NVCN ): FY GAAP EPS of -$15.07. Revenue of $3.81M (+49.4% Y/Y). For further details see: Neovasc GAAP EPS of -$15.07, revenue of $3.81M
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...
2023-03-10 10:28:14 ET Summary I generally like CVR and this is no exception. The CVR is not a sure thing but it does appear to be undervalued by the market. Shareholders have voted yes on the deal and I expect it to close very soon. Several biotech mergers/tenders w...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...
VANCOUVER and MINNEAPOLIS - ( NewMediaWire ) - February 01, 2023 - Neovasc, Inc. (“Neovasc” or “the Company”) ( NASDAQ , TSX : NVCN) today announced the German Institute for the Hospital Remuneration System (“InEK”)...
Shockwave Medical ( NASDAQ: SWAV ) reported preliminary Q4 revenue and outlook for FY2023 which seen above analysts estimates. In addition, Shockwave announced the acquisition of Neovasc ( NASDAQ: NVCN ) for an enterprise value of ~$100M plus certain contingent payment...
Shockwave Medical ( NASDAQ: SWAV ) is acquiring Neovasc ( NASDAQ: NVCN ) for an enterprise value of ~$100M plus certain contingent payments. Canada-based medical device maker Neovasc is developing a minimally invasive treatment for refractory angina — a t...
Neovasc’s Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market Shockwave Medical Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Full Year 2023 Revenue Guidance SANTA CLARA, Calif., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Sh...
VANCOUVER, BC, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Neovasc Inc. (" Neovasc " or the " Company ") (NASDAQ,TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entere...
News, Short Squeeze, Breakout and More Instantly...
Neovasc Inc. (NASDAQ: NVCN) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.48% on the day to $29.23. Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. It...
VANCOUVER and MINNEAPOLIS, MN, March 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today reported financial results for the fourth quarter and year ended December 31, 2022. Recent Hi...
VANCOUVER, BC, March 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive devices for the treatment of refractory angina, is pleased to announce that its Shareholders (as d...